Form 8-K Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K


CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 5, 2014 


Tekmira Pharmaceuticals Corporation
(Exact name of registrant as specified in its charter)

British Columbia, Canada 001-34949 980597776
(State or other jurisdiction
of incorporation)
(Commission File Number) (IRS Employer Identification No.)

100-8900 Glenlyon Parkway
Burnaby, British Columbia
Canada
V5J 5J8
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code:   (604) 419-3200

________________________________________________________________________________
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    [   ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    [   ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    [   ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    [   ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On November 5, 2014 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

    Exhibit 99.1.       Press release dated November 5, 2014


SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Tekmira Pharmaceuticals Corporation
(Registrant)


November 5, 2014
(Date)
  /s/   BRUCE G. COUSINS
Bruce G. Cousins
Executive Vice President and Chief Financial Officer
Tekmira to Host Analyst Day on November 21 in New York City

EXHIBIT 99.1

Tekmira to Host Analyst Day on November 21 in New York City

VANCOUVER, British Columbia, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today it will be hosting an Analyst and Investor Day on Friday, November 21, 2014 in New York City, NY. The presentations will be held between 9 a.m. - 1 p.m. Eastern Time (6 a.m. - 10 a.m. Pacific Time).

The event will include a corporate and financial overview by Dr. Mark Murray, Tekmira's President and CEO and Bruce Cousins, Chief Financial Officer; program development updates by Dr. Ian MacLachlan, Chief Technical Officer and Dr. Mark Kowalski, Chief Medical Officer; as well as an update on Tekmira's discovery efforts by Dr. Mike Abrams, Chief Discovery Officer.

Tekmira's executive management will be accompanied by independent, medical key opinion leaders who will present information on the therapeutic areas relevant to the Company's development programs.

Webcast Information

A live webcast of this event will be available through the investor section of Tekmira's website at www.tekmira.com. A replay of the webcast will be available approximately three hours after the meeting and can be accessed until Dec 31, 2014.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle (LNP) delivery technology to pharmaceutical and biotechnology partners. Tekmira has been working in the field of nucleic acid delivery for over a decade, and has broad intellectual property covering its delivery technology. Further information about Tekmira can be found at www.tekmira.com. Tekmira is based in Vancouver, Canada and Seattle, USA.

CONTACT: Investors
         Julie P. Rezler
         Director, Investor Relations
         Phone: 604-419-3200
         Email: jrezler@tekmira.com

         Media
         Please direct all media inquiries to: media@tekmira.com